VAAST Trademark

Trademark Overview

On Monday, October 1, 2018, a trademark application was filed for VAAST with the United States Patent and Trademark Office. The USPTO has given the VAAST trademark a serial number of 88976041. The federal status of this trademark filing is REGISTERED as of Tuesday, June 30, 2020. This trademark is owned by Vaxart, Inc.. The VAAST trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

RESEARCH AND DEVELOPMENT OF ORAL VACCINES FOR HUMAN; VACCINE FORMULATION SERVICES; RESEARCH AND LABORATORY TESTING INTO THE FORMULATION OF VACCINES ON BEHALF OF OTHERS, AND ANALYTICAL REPORTS
vaast

General Information

Serial Number88976041
Word MarkVAAST
Filing DateMonday, October 1, 2018
Status700 - REGISTERED
Status DateTuesday, June 30, 2020
Registration Number6092713
Registration DateTuesday, June 30, 2020
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, February 26, 2019

Trademark Statements

Certificate of Correction for RegistrationIn the statement, line 1, "California" should be deleted, and "Delaware" should be inserted.
Goods and ServicesRESEARCH AND DEVELOPMENT OF ORAL VACCINES FOR HUMAN; VACCINE FORMULATION SERVICES; RESEARCH AND LABORATORY TESTING INTO THE FORMULATION OF VACCINES ON BEHALF OF OTHERS, AND ANALYTICAL REPORTS

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, October 9, 2018
Primary Code042
First Use Anywhere DateTuesday, October 30, 2018
First Use In Commerce DateTuesday, October 30, 2018

Trademark Owner History

Party NameVaxart, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressSouth San Francisco, CA 94080
Party NameVaxart, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSouth San Francisco, CA 94080
Party NameVaxart, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSouth San Francisco, CA 94080

Trademark Events

Event DateEvent Description
Monday, January 14, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, October 4, 2018NEW APPLICATION ENTERED
Tuesday, October 9, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, January 11, 2019ASSIGNED TO EXAMINER
Wednesday, February 6, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, February 26, 2019PUBLISHED FOR OPPOSITION
Tuesday, February 26, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 23, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, September 18, 2019TEAS POST PUBLICATION AMENDMENT RECEIVED
Tuesday, October 1, 2019TEAS STATEMENT OF USE RECEIVED
Tuesday, October 1, 2019TEAS REQUEST TO DIVIDE RECEIVED
Tuesday, October 1, 2019DIVISIONAL REQUEST RECEIVED
Tuesday, October 1, 2019USE AMENDMENT FILED
Friday, October 18, 2019CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, October 18, 2019DIVISIONAL PROCESSING COMPLETE
Thursday, May 7, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, October 18, 2019STATEMENT OF USE PROCESSING COMPLETE
Thursday, November 7, 2019SU - NON-FINAL ACTION - WRITTEN
Thursday, November 7, 2019NON-FINAL ACTION E-MAILED
Thursday, November 7, 2019NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, May 26, 2020ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Wednesday, May 27, 2020NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Tuesday, June 30, 2020REGISTERED-PRINCIPAL REGISTER
Thursday, July 30, 2020TEAS SECTION 7 REQUEST RECEIVED
Friday, November 20, 2020CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Thursday, May 7, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, May 8, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, November 23, 2020CORRECTION UNDER SECTION 7 - PROCESSED
Monday, June 30, 2025COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED

Related Keywords

vaast research vaccines formulation behalf others analytical reports testing laboratory human